- Article
Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation
- Gabriela Wiergowska,
- Anna Stasiłowicz,
- Andrzej Miklaszewski,
- Kornelia Lewandowska and
- Judyta Cielecka-Piontek
The presence of active pharmaceutical ingredients (APIs) in the forms of different polymorphic states can induce differences in their physicochemical properties. In the case of poorly soluble APIs, like the oncological drug sorafenib tosylate, small...